Multiply Labs
US robotic biomanufacturing company automating gene-modified cell therapy production with multi-arm robot clusters, cutting costs by up to 74%.
Multiply Labs is a San Francisco-based robotic biomanufacturing company founded in 2016 by Fred Parietti and Alice Melocchi. The company develops autonomous robotic systems purpose-built for the industrial-scale manufacturing of advanced therapies, particularly gene-modified cell therapies such as CAR-T. Its core system consists of modular robotic clusters incorporating four collaborative robot arms (from Universal Robots) operating in parallel to automate a broad range of GMP-standard cell therapy instruments.
Compared to legacy manual manufacturing, Multiply Labs' robotic platform delivers up to 74% cost reduction per patient dose and achieves up to 100x more doses per square foot of cleanroom space. The company operates its own GMP-ready robotic manufacturing facility at 1040 Mariposa Street, San Francisco. Key commercial partners and collaborators include AstraZeneca, Kyverna Therapeutics, Legend Biotech, Cytiva, Thermo Fisher Scientific, Charles River Laboratories, and UCSF.
Multiply Labs was featured at NVIDIA GTC 2026, where Jensen Huang highlighted its robotic biomanufacturing capabilities. The company has raised $41.3M across seven funding rounds from investors including Lux Capital, Casdin Capital, Fifty Years, and Garage Capital. Its team of approximately 36 multidisciplinary engineers and pharmaceutical scientists continues to expand robotic automation across the full cell therapy manufacturing workflow.
Primary type & automation activities this supplier delivers:
Robotic Cell Therapy Manufacturing Cluster
Modular robotic cluster with four collaborative arms for automated GMP cell therapy manufacturing, reducing costs by up to 74%.
Contact Multiply Labs
WEBSITE
https://multiplylabs.com/HEADQUARTERS
United States
Company Facts
Founded
2016
Primary Role
Manufacturer
Company Size
-
Primary Region
North America
Annual Sales
-
Funding Stage
-
Funding Total
-
AI for Science 2026: The Global Race for Scientific Discovery
2026 AI for Science landscape report: WAIC 2026 exhibitor breakdown, MIT Boltz-2 and CMU Coscientist case studies, US/China/EU policy comparison, Anthropic Claude Science, and US academic cautionary views.
WAIC 2026: Embodied Intelligence Enters Industrial Deployment Era
WAIC 2026 in Shanghai (July 17–20) saw 200+ embodied intelligence companies, 300+ live robots, and first confirmed humanoid deployments in logistics and pharmacy. RobotToday engineering analysis.
Digital Twin, Physical AI & Robot OEM Readiness 2026: Platforms, VLA Models, LLM Programming
A balanced analysis of the robot intelligence revolution: multi-vendor digital twin platforms (NVIDIA, Siemens, Dassault, ABB, Rockwell, Hexagon), Physical AI VLA models (RT-2, pi0, GR00T N1, AgiBot), current Physical AI limitations, LLM robot programming, and the OEM readiness matrix across US, European, and Chinese manufacturers.
Integrated Joint Actuators 2026: Technology, Global Suppliers & China's Leap Forward
From rotary joints hitting 530 N·m+ to linear joints with planetary roller screws, integrated actuators are replacing the three-part drivetrain. Full supplier map: Tihu, PhyArc, RobStride, Schaeffler, maxon — and China's path from 1,000-RMB modules to global standard-setter.
Laboratory Robotics in 2026: Technology, Companies & Vertical Maturity
From clinical diagnostics to self-driving labs: a deep analysis of laboratory robotics technologies, mass-production maturity timelines across 12 vertical sectors, 26 key companies, and the investment landscape shaping lab automation through 2030.
Agricultural Robotics: Crop Monitoring and Aerial Scouting
An evidence-based deep dive into the crop monitoring and aerial scouting segment of agricultural robotics. Covers the market opportunity (ex-China) across North America, EU, Japan, and Israel; key players including Taranis, BASF xarvio, and DJI; emerging technologies such as edge AI, hyperspectral imaging, and satellite–drone fusion; and the structural challenges limiting wider adoption — connectivity gaps, false positives, data fragmentation, and small-farm exclusion.
RoboMME Benchmark Reveals a Critical Weakness in Robot AI: Memory
A new RoboMME benchmark study reveals that modern robot AI still struggles with memory — an emerging bottleneck for generalist and humanoid robotics.
The OpenClaw Test: Which Humanoid Robotics Companies Will Survive 2026?
How OpenClaw's AI agent orchestration exposes which humanoid robotics companies have genuine hardware innovation vs. expensive commodity robots with proprietary software.
Where Engineers Can Enter Robotics in 2026
Robotics hiring in 2026 is driven by deployment, integration, and operations—not hype. A structural map of real entry points for engineers.
AI’s Next Revolution: Multiply Labs Is Scaling Robotics-Driven Cell Therapy Biomanufacturing Labs
A startup is collaborating with prominent cell therapy companies to revolutionize the manufacturing process within clean rooms by integrating robotics technology. This innovative approach is set to significantly lower production costs by over 70% and enhance output efficiency compared to traditional manufacturing systems. The initiative aims to address the growing demand for cell therapies, which require precise and sterile environments for production. By leveraging advanced robotics, the startup is not only streamlining operations but also positioning itself as a key player in the rapidly evolving biotechnology sector. This development is particularly timely, as the industry seeks to meet increasing patient needs while maintaining high-quality standards in cell therapy manufacturing.
How Mimic Robotics is Bringing Physical AI to Dexterous Manipulation
Mimic Robotics combines dexterous robotic hands with foundation-model Physical AI to automate human-like manipulation tasks in industry with scalable learning.
